The University of Southampton
University of Southampton Institutional Repository

HLA-DPB1 glutamate 69: a genetic marker of beryllium disease

HLA-DPB1 glutamate 69: a genetic marker of beryllium disease
HLA-DPB1 glutamate 69: a genetic marker of beryllium disease
Chronic beryllium disease (CBD) is a lung disorder related to beryllium exposure and is characterized by the accumulation in the lung of beryllium-specific CD4+ major histocompatibility complex (MHC) class II-restricted T lymphocytes. Evaluation of MHC class II genes in 33 CBD cases and 44 controls has shown a negative association with HLA-DPB1*0401 (P < 0.001) and a positive association with HLA-DPB1*0201 (P < 0.05) alleles, which differ at residues 36, 55 to 56, and 69 of the beta 1 chain. Among CBD cases, 97 percent expressed the HLA-DPB1*0201-associated glutamic acid (unaffected population, 30 percent; P < 0.001) at residue 69, a position involved in susceptibility to autoimmune disorders. This suggests that HLA-DP has a role in conferring susceptibility and that residue 69 of HLA-DPB1 could be used in risk assessment for CBD.
0036-8075
242-244
Richeldi, L.
47177d9c-731a-49a1-9cc6-4ac8f6bbbf26
Sorrentino, R.
b6c52d74-0e96-45fa-8f02-5c3fcd2f3f11
Saltini, C.
511217a8-2901-4ca3-bbdf-b54611e4acc2
Richeldi, L.
47177d9c-731a-49a1-9cc6-4ac8f6bbbf26
Sorrentino, R.
b6c52d74-0e96-45fa-8f02-5c3fcd2f3f11
Saltini, C.
511217a8-2901-4ca3-bbdf-b54611e4acc2

Richeldi, L., Sorrentino, R. and Saltini, C. (1993) HLA-DPB1 glutamate 69: a genetic marker of beryllium disease. Science, 262 (5131), 242-244. (doi:10.1126/science.8105536). (PMID:8105536)

Record type: Article

Abstract

Chronic beryllium disease (CBD) is a lung disorder related to beryllium exposure and is characterized by the accumulation in the lung of beryllium-specific CD4+ major histocompatibility complex (MHC) class II-restricted T lymphocytes. Evaluation of MHC class II genes in 33 CBD cases and 44 controls has shown a negative association with HLA-DPB1*0401 (P < 0.001) and a positive association with HLA-DPB1*0201 (P < 0.05) alleles, which differ at residues 36, 55 to 56, and 69 of the beta 1 chain. Among CBD cases, 97 percent expressed the HLA-DPB1*0201-associated glutamic acid (unaffected population, 30 percent; P < 0.001) at residue 69, a position involved in susceptibility to autoimmune disorders. This suggests that HLA-DP has a role in conferring susceptibility and that residue 69 of HLA-DPB1 could be used in risk assessment for CBD.

Full text not available from this repository.

More information

Published date: 8 October 1993
Organisations: Clinical & Experimental Sciences

Identifiers

Local EPrints ID: 368933
URI: http://eprints.soton.ac.uk/id/eprint/368933
ISSN: 0036-8075
PURE UUID: 2abb0e60-7b96-45df-b747-d7c1ca200b65

Catalogue record

Date deposited: 23 Sep 2014 11:21
Last modified: 18 Jul 2017 01:41

Export record

Altmetrics

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×